News from pharmathene, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 10, 2014, 09:03 ET

PharmAthene Awarded Contract Of Up To $28.1 Million To Develop Next Generation Thermostable Anthrax Vaccine

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced...

Sep 09, 2014, 09:03 ET

New Non-Clinical Data Demonstrate SparVax® Provides Equivalent Protection In Head-To-Head Comparison With BioThrax®

PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax® anthrax vaccine program were...

Sep 08, 2014, 12:33 ET

PharmAthene To Present At Rodman & Renshaw And Aegis Capital Corporation 2014 Investment Conferences

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced...

Sep 08, 2014, 10:13 ET

PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs

 PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have...

Aug 10, 2014, 07:13 ET

Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that on August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and...

Aug 04, 2014, 16:02 ET

PharmAthene Reports Second Quarter 2014 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Jun 09, 2014, 10:30 ET

PharmAthene Granted U.S. Patent For Recombinant Bioscavenger

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to...

Jun 04, 2014, 10:30 ET

PharmAthene Presents New SparVax® Anthrax Vaccine Data At The FDA Medical Countermeasures Initiative Symposium

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax® anthrax vaccine program were recently presented at the 2014...

May 29, 2014, 10:29 ET

PharmAthene Presents New SparVax® Anthrax Vaccine Data At The American Society For Microbiology 2014 Meeting

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax® anthrax vaccine program were presented...

May 08, 2014, 16:02 ET

PharmAthene Reports First Quarter 2014 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Apr 07, 2014, 09:00 ET

PharmAthene Updates Status Of SparVax® Anthrax Vaccine Contract

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS),...

Apr 01, 2014, 14:42 ET

PharmAthene Presents SparVax® Anthrax Vaccine Data at the New Technologies New Vaccines 2014 Conference

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax® next-generation anthrax vaccine program were...

Mar 11, 2014, 16:00 ET

PharmAthene Reports Year-End 2013 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Mar 10, 2014, 12:20 ET

PharmAthene to Host Year-End 2013 Conference Call and Webcast on Tuesday, March 11, 2014

 PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats,...

Dec 16, 2013, 08:00 ET

PharmAthene Receives FDA Notification On SparVax®

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced...

Dec 02, 2013, 09:00 ET

PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has terminated its definitive merger agreement with Theraclone Sciences, Inc. with...

Nov 11, 2013, 09:47 ET

New PharmAthene SparVax® Anthrax Vaccine Data Published In Clinical and Vaccine Immunology

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Nov 07, 2013, 16:30 ET

PharmAthene Reports Third Quarter 2013 Financial And Operational Results

  Recent Highlights - On track to commence SparVax® Phase 2 clinical trial - Presented new SparVax® anthrax vaccine...

Sep 13, 2013, 08:34 ET

New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax® next-generation anthrax...

Sep 09, 2013, 08:20 ET

PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission

PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange...